Reliance Life Sciences plans to set up an active pharmaceutical ingredients and formulations manufacturing complex at Jamnagar.
The complex will come up in the multi-product special economic zone being established by Reliance Industries.
The manufacturing complex will focus on the export markets where Reliance has a presence.
While company executives refused to divulge further details, industry sources said that Reliance has earmarked a huge area in the SEZ for the project.
The exact investment is not known. The new unit in Jamnagar is likely to manufacture products in the field of medical, plant and industrial biotechnology.
RLS is developing a range of biopharmaceutical products especially blood pharma proteins, bio-generic recombinant proteins, humanised monoclonal antibodies and siRNA molecules.
It markets biopharmaceutical products such as albumin, fibrin sealants and immunoglobulin, anti-hemophilic factor, virus inactivated plasma under Reliance brand.
There are around 15 products at various stages of development, according to industry sources, some of which may be manufactured at the proposed unit.
The complex will also have a unit of contract research organisation, Reliance Clinical Research Services, a wholly-owned subsidiary of RLS with global headquarters at Newtown, Pennsylvania and facilities in Chicago, Bangalore and Navi Mumbai.
The unit will have facilities to conduct clinical trial and monitoring, pharmacovigilance, biometrics and regulatory affairs.
